EDAP Appoints Senior Marketing Director; Company to Increase Marketing Efforts to Patients and Physicians Across Europe

LYON, France, Sept. 22  /PRNewswire-FirstCall/ -- EDAP TMS S.A. (NASDAQ:EDAP), the world leader in High Intensity Focused Ultrasound treatment of localized prostate cancer, is pleased to announce the appointment of Fabrice Romano to the position of Senior Marketing Director.  In this role, Romano will direct market education programs aimed at doctors and patients in new and existing markets for EDAP's Ablatherm-HIFU product.  He will also direct documentation of Ablatherm-HIFU clinical data for distribution in marketing programs, support the sales force in building markets and assist in accelerating reimbursement process in key European countries.

Romano was previously the European marketing manager for Sofradim, a leading French company in manufacturing surgical implants used in general and uro-gynecological surgery, where he oversaw the distribution network and developed marketing efforts directed at key opinion leaders.  Romano has also served as marketing and sales manager for Biomatech, a private lab for the development and testing of medical devices and Domilens, now Bausch & Lomb Surgical, as sales manager for France.  He also has direct experience in developing marketing, communication and training multimedia tools for pharmacy and medical device manufacturers, including Pfizer, Johnson & Johnson, Novartis, Wyeth and Medtronic, while directing his own company, Multi Active. He is a 1987 graduate of the French Veterinary Schools specializing in ophthalmology and microsurgery.  He has been working since 1989 in the human healthcare field.  Romano is fluent in French, Italian and English.

"Joining EDAP is an amazing opportunity to be involved in a business challenge which consists of convincing the worldwide urology community that our HIFU technology is certainly the best alternative for localized prostate cancer treatment, combining excellent results and a very low rate of side effects," Romano said.  "EDAP has already accumulated a significant body of clinical evidence and support of key urology opinion leaders in many countries.  There is clearly strong momentum moving Ablatherm forward into the mainstream of prostate cancer treatment."

Hugues de Bantel, EDAP's Chief Executive Officer, commented, "EDAP has made significant progress in developing treatment centers across Europe over the past several years.  Adding a Director of Marketing allows us to more aggressively address the marketplace and build knowledge of the unique benefits Ablatherm-HIFU offers as well as grow interest in the patient population by informing them of the lower side effects and quick recovery available to them in treating prostate cancer.  Fabrice has a unique background in growing the markets for medical devices by communicating with both patients and doctors, which will serve EDAP well as we continue to establish more centers in countries currently using Ablatherm and develop new markets worldwide."

About EDAP TMS S.A.

EDAP TMS S.A. develops and markets Ablatherm, the most advanced and clinically proven choice for High Intensity Focused Ultrasound (HIFU) treatment of localized prostate cancer.  HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects.  The company is also developing this technology for the treatment of certain other types of tumors.  EDAP TMS S.A. also produces and commercializes medical equipment for treatment of urinary tract stones using Extra-corporeal Shockwave Lithotripsy (ESWL).

For more information on the Company, contact the Investor Relations Dept by phone at [phone] or see the Company's Web site at: http://www.edap-tms.com/ .

This press release contains, in addition to historical information, forward-looking statements that involve risks and uncertainties.  These include statements regarding the Company's growth and expansion plans.  Such statements are based on management's current expectations and are subject to a number of uncertainties and risks that could cause actual results to differ materially from those described in the forward-looking statements.  Factors that may cause such a difference include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission.

   CONTACT:    EDAP TMS S.A.
               Hugues de Bantel - Philippe Chauveau
               Blandine Confort
               [phone]

               Halliburton Investor Relations
               Matt Kreps - Geralyn DeBusk
               972 458 8000


DATASOURCE: EDAP TMS S.A.



CONTACT:  Hugues de Bantel, or Philippe Chauveau, or Blandine Confort,

all of EDAP TMS S.A., [phone]; or Matt Kreps or Geralyn DeBusk, both

of Halliburton Investor Relations, [phone], for EDAP TMS S.A.



Web site:  http://www.edap-tms.com/ 

Copyright